Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs

BACKGROUND: Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Geurden, Thomas, Six, Robert, Becskei, Csilla, Maeder, Steven, Lloyd, Anne, Mahabir, Sean, Fourie, Josephus, Liebenberg, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588728/
https://www.ncbi.nlm.nih.gov/pubmed/28877743
http://dx.doi.org/10.1186/s13071-017-2358-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588728/
https://www.ncbi.nlm.nih.gov/pubmed/28877743
http://dx.doi.org/10.1186/s13071-017-2358-3

Ejemplares similares